Les cinq publications les plus percutantes de 2024 et de cette année pour la pratique clinique
Résumé
Cette dernière année a vu la publication d’un certain nombre d’articles extrêmement influents qui ont eu un impact immédiat sur la façon dont nous soignons les patients atteints de maladies inflammatoires de l’intestin (MII). Dans cet article, j’ai sélectionné cinq publications sur des études parues depuis le début de l’année 2024, qui ont déjà eu un impact direct sur ma façon de prendre en charge les personnes atteintes de MII. Ces publications sont une lecture incontournable pour tous les médecins canadiens qui traitent les MII.
Références
Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002-1014. doi:10.1016/s2468-1253(21)00312-5
Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut. 2023;72(2):264-274. doi:10.1136/gutjnl-2022-328052
Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022;162(2):482-494. doi:10.1053/j.gastro.2021.10.037
Targownik LE, Bernstein CN, Benchimol EI, Kaplan GG, Singh H, Tennakoon A, et al. Earlier anti-TNF initiation leads to long-term lower health care utilization in Crohn’s disease but not in ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(11):2607-2618.e2614. doi:10.1016/j.cgh.2022.02.021
Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415-427. doi:10.1016/s2468-1253(24)00034-7
Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, et al. Early indolent course of Crohn’s disease in newly diagnosed patients is not rare and possibly predictable. Clin Gastroenterol Hepatol. 2021;19(8):1564-1572.e1565. doi:10.1016/j.cgh.2020.06.069
Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn’s disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9(6):521-538. doi:10.1016/s2468-1253(24)00044-x
Yang H, Huang Z, Li M, Zhang H, Fu L, Wang X, et al. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn’s disease: a multicenter cohort study. eClinicalMedicine. 2023;66. doi:10.1016/j.eclinm.2023.102337
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433-446. doi:10.1038/s41575-023-00768-1
D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/s0140-6736(22)00467-6
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease. N Engl J Med. 2024;391(3):213-223. doi:10.1056/NEJMoa2314585
Kalman TD, Everhov ÅH, Nordenvall C, Sachs MC, Halfvarson J, Ekbom A, et al. Decrease in primary but not in secondary abdominal surgery for Crohn’s disease: nationwide cohort study, 1990–2014. Br J Surg. 2020;107(11):1529-1538. doi:10.1002/bjs.11659
Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996-1006. doi:10.1053/j.gastro.2013.07.041
Nardone OM, Calabrese G, Barberio B, Giglio MC, Castiglione F, Luglio G, et al. Rates of endoscopic recurrence in postoperative Crohn’s disease based on anastomotic techniques: a systematic review and meta-analysis. Inflamm Bowel Dis. 2024;30(10):1877-1887. doi:10.1093/ibd/izad252
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956-963. doi:10.1016/0016-5085(90)90613-6
Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014;12(9):1494-1502 e1491. doi:10.1016/j.cgh.2013.12.035
Collins M, Sarter H, Gower-Rousseau C, Koriche D, Libier L, Nachury M, et al. Previous exposure to multiple anti-TNF is associated with decreased efficiency in preventing postoperative Crohn’s disease recurrence. J Crohn’s Colitis. 2016;11(3):281-288. doi:10.1093/ecco-jcc/jjw151
D’Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, et al. Vedolizumab to prevent postoperative recurrence of Crohn’s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025;10(1):26-33. doi:10.1016/S2468-1253(24)00317-0
Tsai L, Nguyen NH, Ma C, Prokop LJ, Sandborn WJ, Singh S. Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn’s disease in population-based cohort studies. Dig Dis Sci. 2022;67(6):2451-2461. doi:10.1007/s10620-021-07200-1
Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, et al. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study. United European Gastroenterol J. 2021;9(4):507-516. doi:10.1177/2050640620977405
Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103-110. doi:10.1016/j.cgh.2006.09.033
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237-243. doi:10.1136/gutjnl-2016-313060
Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, et al. Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19(3):511-518.e516. doi:10.1016/j.cgh.2020.03.072
Gibson DJ, Doherty J, McNally M, Campion J, Keegan D, Keogh A, et al. Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol. 2020;11(6):441-447. doi:10.1136/flgastro-2019-101335
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(11):981-996. doi:10.1016/S2468-1253(24)00200-0
Gecse K, Van Oostrom J, Rietdijk S, Frigstad SO, Doherty G, Irving P, et al. DOP056 TDM-based dose-intensification of infliximab is not superior to standard dosing in patients with acute severe ulcerative colitis: results from the TITRATE study. Journal of Crohn’s and Colitis. 2025;19(Supplement_1):i194-i195. doi:10.1093/ecco-jcc/jjae190.0095
Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, et al. Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024. Published online March 27, 2024. doi:10.14309/ajg.0000000000002674
Ban L, Tata LJ, Humes DJ, Fiaschi L, Card T. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther. 2015;42(7):855-866. doi:10.1111/apt.13354
Ali MF, He H, Friedel D. Inflammatory bowel disease and pregnancy: fertility, complications and treatment. Ann Gastroenterol. 2020;33(6):579-590. doi:10.20524/aog.2020.0536
Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150(3):734-757 e731. doi:10.1053/j.gastro.2015.12.003
Mårild K, Söderling J, Stephansson O, Axelrad J, Halfvarson J, Bröms G, et al. Histologic remission in inflammatory bowel disease and female fertility: a nationwide study. Gastroenterology. 2024;166(5):802-814.e818. doi:10.1053/j.gastro.2024.01.018
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian IBD Today 2025
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
